NICE Rejects Javlor, But Could Products For Unmet Clinical Needs Be Rethought?

This article was originally published in The Pink Sheet Daily

29 Nov 2010
News

The Pink Sheet Daily pinkeditor@informa.com

Executive Summary

U.K. cost watchdog rejects Pierre Fabre's Javlor even though it extended the survival of patients with metastatic bladder cancer.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
BioPharmaceutical

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS071505

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS071505

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

NICE Rejects Javlor, But Could Products For Unmet Clinical Needs Be Rethought?

News

Executive Summary

Related Content

NICE Continues Tough Approach On Cancer Drugs, Rejects Tarceva, Javlor and Yondelis

NICE Continues Tough Approach On Cancer Drugs, Rejects Tarceva, Javlor and Yondelis

UK's New Cancer Drug Fund Might Not Alleviate Regional Access Disparities

Roche To Appeal NICE's Rejection Of Herceptin For HER2-positive Stomach Cancer

Roche To Appeal NICE's Rejection Of Herceptin For HER2-positive Stomach Cancer

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert